COVID-19后侵袭性真菌性鼻窦炎:一种新的临床实体
这项前瞻性纵向研究纳入36例近期感染COVID-19后诊断为急性侵袭性真菌性鼻窦炎的患者,平均年龄52.92±11.30岁。最常见基础疾病为糖尿病(27.8%),霉菌分析显示毛霉和曲霉感染分别占77.8%和30.6%。所有患者接受手术清创联合抗真菌药物治疗(2例PCR阳性者仅药物治疗),总生存率为63.89%(23/36)。
要点
- COVID-19后患者出现急性侵袭性真菌性鼻窦炎需高度警惕,早期诊断和治疗至关重要。
- 最常见基础疾病为糖尿病,毛霉和曲霉是最常见病原体。
- 手术清创联合抗真菌治疗可提高生存率,总生存率63.89%。
核心结论
- 对COVID-19患者临床怀疑急性侵袭性真菌性鼻窦炎并早期给予抗真菌治疗和手术清创,对改善预后和提高生存率至关重要。
研究设计与样本
- 前瞻性纵向研究,纳入36例近期COVID-19感染后诊断为急性侵袭性真菌性鼻窦炎的患者,平均年龄52.92±11.30岁。
主要发现
- 最常见基础疾病为糖尿病(27.8%)。
- 霉菌分析显示毛霉和曲霉感染分别占77.8%和30.6%。
- 鼻窦鼻腔、眶、脑和腭部受累分别占100%、80.6%、27.8%和33.3%。
- 最常见症状和体征为面部疼痛(75%)、面部麻木(66.7%)、眼肌麻痹和视力丧失(63.9%)。
- 总生存率为63.89%(23/36)。
关键数值与推荐
- 抗真菌药物包括两性霉素B、伏立康唑和/或泊沙康唑。
- 手术治疗仅限于COVID-19 PCR阴性患者,采用内镜、开放或联合入路。
- 2例COVID-19 PCR阳性患者仅接受抗真菌治疗。
临床怎么用
- 对COVID-19后患者出现面部疼痛、麻木、眼肌麻痹或视力丧失等症状时应怀疑急性侵袭性真菌性鼻窦炎。
- 早期联合抗真菌治疗和手术清创可改善生存率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Occurrence of invasive fungal respiratory superinfections in patients with COVID-19 has gained increasing attention in the latest studies. Yet, description of acute invasive fungal sinusitis with its management in those patients is still scarce. This study aims to describe this recently increasing clinical entity in relation to COVID-19 patients. STUDY DESIGN: Longitudinal prospective study. METHODS: Prospective longitudinal study included patients diagnosed with acute invasive fungal rhinosinusitis after a recent COVID-19 infection. Antifungal agents given included amphotericin B, voriconazole, and/or posaconazole. Surgical treatment was restricted to patients with PCR negative results for COVID-19. Endoscopic, open, and combined approaches were utilized to eradicate infection. Follow-up for survived patients was maintained regularly for the first postoperative month. RESULTS: A total of 36 patients with a mean age of 52.92 ± 11.30 years old were included. Most common associated disease was diabetes mellitus (27.8%). Mycological analysis revealed infection with Mucor and Aspergillus species in 77.8% and 30.6% of patients, respectively. Sino-nasal, orbital, cerebral, and palatine involvement was found in 100%, 80.6%, 27.8%, and 33.3% of patients, respectively. The most common reported symptoms and signs are facial pain (75%), facial numbness (66.7%), ophthalmoplegia, and visual loss (63.9%). All patients were treated simultaneously by surgical debridement with antifungal medications except for two patients with PCR-positive swab for COVID-19. These two patients received antifungal therapy alone. Overall survival rate was 63.89% (23/36). CONCLUSION: Clinical suspicion of acute invasive fungal sinusitis among COVID-19 patients and early management with antifungal therapy and surgical debridement is essential for better outcomes and higher survival. LEVEL OF EVIDENCE: 4 Laryngoscope, 131:2652-2658, 2021.
引用
- El-Kholy NA, El-Fattah AMA, Khafagy YW, et al. Invasive Fungal Sinusitis in Post COVID-19 Patients: A New Clinical Entity. Laryngoscope. 2021. PMID: 34009676. doi:10.1002/lary.29632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。